Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AaiPharma Fast-Acting Diclofenac NDA Filing Planned For 2002

Executive Summary

AaiPharma plans to submit an NDA by the end of 2002 for its rapidly absorbed diclofenac, claiming a shorter time-to-peak benefit in acute pain.

You may also be interested in...



Patent Reform Bill Drops Changes To Injunctive Relief In Revised Draft

The latest draft of Rep. Lamar Smith's (R-Texas) "Patent Reform Act" drops proposed changes to injunctive relief standards that had been opposed by the pharmaceutical industry

Patent Reform Bill Drops Changes To Injunctive Relief In Revised Draft

The latest draft of Rep. Lamar Smith's (R-Texas) "Patent Reform Act" drops proposed changes to injunctive relief standards that had been opposed by the pharmaceutical industry

Barr Fluoxetine Goal: 80% Generic Penetration In First Six Months

Barr hopes to achieve 80% generic substitution for Lilly's Prozac within the first six months after launch of its generic 20 mg fluoxetine capsules.

Related Content

UsernamePublicRestriction

Register

OM007016

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel